Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment

Gaddy, Jacquelyne; Gross, Cary P.

doi:10.1001/jamaoncol.2022.5006

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If this situation is left without regulatory intervention, it is likely to become more profound. Regulatory pressure has been attempted in bringing attention to race and sex disparities in clinical trial enrollment in the past, 7 but we are still waiting for a similar intervention concerning geographic disparities in access to these trials. In addition, non-industry funding through government and/or academic grants dedicated to cancer clinical research should be tied to optimizing the access of patients in remote and rural areas for these studies.…”

Section: Discussionmentioning

confidence: 99%

Geographic Disparities in Access to Cancer Clinical Trials in Canada

Abdel-Rahman

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: This study aims to evaluate geographic disparities in access to cancer clinical trials across Canada. Methods: Cancer clinical trial data recorded within the clinicaltrials.gov and reporting the conduct of any of these trials in Canada, 2005 to 2023 were reviewed. Frequency analyses of the number of clinical trials that were registered on clinicaltrials.gov for Canada, individual Canadian provinces, main Canadian urban centers, and different cancer types, according to the funding source (industry versus non-industry), as well as according to different periods (using 3-y intervals) were conducted. Moreover, a comparison of cancer clinical trials per 10,000 persons was done between Canada and the United States. Results: The number of cancer clinical trials per 10,000 individuals (according to the 2021 census) in each province/territory varied between 6.79 (New Brunswick) to 0 (the 3 territories). The number of cancer clinical trials in relation to 1000 projected cancer cases for some of the common tumor types in Canada was then reviewed. The highest number was for lymphoma clinical trials (32.85), whereas the lowest number was for bladder cancer clinical trials (7.06). Most of the trials have industry funding (69%). Using 3-year intervals, the highest number of cancer clinical trials was observed from 2014 to 2016 (778 trials), and the lowest number was observed from 2020 to 2022 (633 trials). Conclusions: Access to clinical trials in Canada is not equitably distributed, with geographical and primary tumor site disparities. Moreover, access to cancer clinical trials has been negatively impacted during the time of the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Geographic Disparities in Access to Cancer Clinical Trials in Canada

Abdel-Rahman

2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The FDA must also engage stakeholders to address societal barriers to trial enrollment, including systemic racism, trial site locations, and mistrust in research. 9…”

Section: Data Gapsmentioning

confidence: 99%

“…To be sure, defining adequate representation, setting enrollment goals, and improving access to demographic data are necessary measures but insufficient to fully remedy trial access inequities. The FDA must also engage stakeholders to address societal barriers to trial enrollment, including systemic racism, trial site locations, and mistrust in research …”

Section: Data Gapsmentioning

confidence: 99%